

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[← Back](#)

Newsroom [View All Our Content & Treatment](#)
[Refer a Patient](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

[Learn more](#)



[Memorial Sloan Kettering Cancer Center Ranked the Best Cancer Center in the Northeast and First in the Nation for Urology Care by U.S. News & World Report](#)

Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the best cancer center in the northeast, the number two hospital for cancer care in the nation, and the number one hospital nationally for urology care by U.S. News & World Report in its annual Best Hospitals listing.



[MSK's Sloan Kettering Institute Celebrates 75 Years of Discovery](#)

Over the last seven and a half decades, researchers at the Sloan Kettering Institute have made important contributions to the fundamental understanding of human biology, as well as driven practice-changing innovations in the treatment of cancer.

Press Releases




[Jeffrey Drebin, MD, PhD, Named President-Elect of the American Surgical Association](#)

An internationally recognized surgeon-scientist, Dr. Drebin has been named 2024 President-Elect of the American Surgical Association.



[New Phase 1 Data from Memorial Sloan Kettering Cancer Center Shows an Investigational Cancer Vaccine May Elicit Lasting Immune Response in Patients with Pancreatic Cancer](#)

New data presented today by Memorial Sloan Kettering Cancer Center (MSK) researchers show an experimental approach to treating pancreatic cancer with the messenger RNA (mRNA)-based therapeutic cancer vaccine candidate, autogene cevumeran, continues to show potential to stimulate an immune response that may reduce the risk of the disease returning after surgery.



[Memorial Sloan Kettering Cancer Center Experts to Present Leading-Edge Research at the American Association for Cancer Research Annual Meeting 2024](#)

Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer discovery during the American Association for Cancer Research (AACR) Annual Meeting on April 5-10 in San Diego, California.


[View all press releases](#)

Articles



[MSK News Winter 2024](#)

MSK is pushing the frontier to help patients like Antonio.



[MSK's New Cancer Engineering PhD Program Is First of Its Kind](#)

Learn about MSK's visionary new cancer engineering PhD Program.



[How MSK's Rapid Diagnosis Got Kieran Treated Quickly for Lymphoma](#)

Kieran Healy was feeling worse by the day. A new father at 43 years old, he was bone-tired and losing weight. He had night sweats and a strange lump in his belly. His local hospital in Manhattan ordered an ultrasound and a CT (computed tomography) scan — but they were scheduled over a month away.

[View all articles](#)

2022 Annual Report: It Takes MSK




[The Rectal Cancer Clinical Trial at MSK That Changed Everything for Its Patients](#)

Learn how a heralded clinical trial that made rectal cancer disappear for every participant is being expanded at Memorial Sloan Kettering Cancer Center. The trial uses only immunotherapy that targets a rare mutation — without the need for surgery, chemotherapy, or radiation.



[A Major Advance in Treating Metastatic Breast Cancer](#)

MSK-led research could change the practice of medicine for millions of people whose breast cancer has spread. Research led by Dr. Shanu Modi has demonstrated that a targeted drug called trastuzumab deruxtecan blocks the protein HER2 even when its levels are low — the case for about 55% of people with breast cancer.



[New Understanding of Cancer's Most Infamous Gene Could Help Stop Tumors Earlier](#)

The protein made by the p53 gene helps guard the body against cancer, in part by detecting and repairing damaged DNA. Over the 30 years since p53 was first discovered, it has remained a stubborn mystery, resisting efforts to tease apart exactly how the loss of the gene's protection leads to the development of cancer. In August 2022, researchers in the Sloan Kettering Institute were able to provide some new answers that hint at new avenues for treatment.

[View the full report](#)



Cancer Straight Talk Podcast from MSK

Cancer Straight Talk brings together national experts and cancer patients to have straightforward, evidence-based conversations. Medical oncologist Diane Reidy-Lagunes hosts this series with the mission of educating and empowering patients to make the right decisions and live happier, healthier lives.

[Listen to the podcast](#)

Stay Informed.

Get the latest news and updates on MSK's cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.

[Newsletter Sign Up](#)

NEXT

[In the News](#)

▼ Connect

[Contact us](#)

[Locations](#)

APPOINTMENTS

[800-525-2225](#)



▼ About MSK

[About us](#)

[Careers](#) ■

[Giving](#) ■

▼ Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

▼ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) ■

[Graduate medical education](#)

[MSK Library](#) ■

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center